A pilot protocol of a calcineurin-inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function

Clinical Transplantation

Volumn 17, Issue SUPPL. 9, 2003, Pages 31-34

  Shaffer, David ^a   Langone, Anthony ^a   Nylander, William A ^a   Goral, Simin ^a   Kizilisik, A Tarik ^a   Helderman, J Harold ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Delayed graft function; Kidney transplantation; Marginal donor kidneys; Sirolimus; Thymoglobulin

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CREATININE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTERSTITIAL PNEUMONIA; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY TRANSPLANTATION; LYMPHOCELE; MALE; NEPHROTOXICITY; PILOT STUDY; PRIORITY JOURNAL; RECIPIENT; SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; WOUND INFECTION;

ADULT; AGED; CALCINEURIN; CLINICAL PROTOCOLS; CYCLOSPORINE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; PILOT PROJECTS; PREDNISONE; RECOVERY OF FUNCTION; SIROLIMUS; TACROLIMUS;

EID: 0043123394     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.17.s9.5.x     Document Type: Article

References (8)

1. Hong JC, Kahan BD. A calcineurin antagonist-free induction strategy for immunosuppresssion in cadaveric kidney transplant recipients at risk for delayed graft function. Transplantation 2001: 71: 1320.
2. Flechner SM, Goldfarb DA, Modlin C et al. A prospective randomized trial of sirolimus vs. cyclosporine in kidney transplantation: Impact of calcineurin inhibitor elimination on renal function (Abstract), May 11-16. Chicago, IL: American Society of Transplantation, 2001.
3. Kreis H, Cisterne J-M, Land W et al. Sirolimus in association with Mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000: 69: 1252.
4. Kahan BD, Rajagopalan PR, Hall M et al. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 1999: 67: 276.
5. Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998: 338: 161.
6. Brennan DC, Flavin K, Lowell J et al. A randomized, double-blinded comparison of thymoglobulin vs. ATGAM for induction immunosuppression therapy in adult renal transplant recipients. Transplantation 1999: 67: 1001.
7. Ojo AO, Meier-Kriesche H-U, Okechukwu CN et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001: 12: 589.
8. Agha IA, Rueda J, Alvarez A et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation 2002: 73: 473.